China to inject billions into grassroots health services
This article was originally published in Scrip
A new initiative under China's health care reform program, which over the past few years has helped propel the country's pharmaceutical sector to astonishing 20%-plus growth rates, was launched by China's influential policy czar, the National Development and Reform Commission (NDRC), on the eighth day of the eighth month (8 August), a date deemed lucky in China.
You may also be interested in...
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.